MAHOGANY: A PHASE 3 TRIAL OF ZANUBRUTINIB PLUS ANTI‐CD20 VERSUS LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMA

Bibliographic Details
Title: MAHOGANY: A PHASE 3 TRIAL OF ZANUBRUTINIB PLUS ANTI‐CD20 VERSUS LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMA
Authors: Sehn, L., Sarkozy, C., Song, Y., Salar, A., Trotman, J., Zinzani, P. L., Zhang, J., Zhang, W., Fustier, P., Delarue, R., Nastoupil, L.
Source: Hematological oncology. 41:168-170
Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100185971959.0x000001&indx=1&recIds=ETOCvdc_100185971959.0x000001
Database: British Library Document Supply Centre Inside Serials & Conference Proceedings
More Details
ISSN:02780232
Published in:Hematological oncology
Language:English